Cullgen’s oncology portfolio features TRK, GSPT1 and CDK2 degraders.

The Maestra-2 trial will test INCB123667 in platinum-resistant ovarian cancer.

For $850m up front Roche gets to challenge Pfizer.

Incyte’s first substantial data with INCB123667 are eclipsed by Pfizer’s PF-07104091/atirmociclib combo.

Just-released abstracts leave investors hungry for details on BLU-222 and CB-010.

Despite a growing presence outside cancer, the company wants to stay true to its “DNA”.

Several companies have followed Pfizer into CDK2 inhibitor development, but the jury is out on this field’s promise.